Literature DB >> 3897170

Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.

A Bauernfeind.   

Abstract

The in-vitro activity of Sch 34343 was compared with that of imipenem, cefpirome and cefotaxime against clinical isolates of important bacterial pathogens. Sch 34343 was very stable to changes in media, human serum concentration, pH and inoculum size. Enterobacteriaceae, including strains resistant to aminopenicillins and established cephalosporins, were susceptible to Sch 34343. In the case of Acinetobacter spp., imipenem was the only highly active antibiotic. Pseudomonas aeruginosa (and most other Pseudomonas spp.) were insensitive to Sch 34343. Activity against Haemophilus influenzae was greater than that of imipenem but less than that of cefotaxime and cefpirome. Sch 34343 activity against Gram-negative anaerobic rods was greater than that of cefoxitin and comparable to imipenem. All methicillin-sensitive staphylococci were inhibited by 1 mg/l of Sch 34343, 0.5 mg/l of imipenem, 2 mg/l of cefpirome and 8 mg/l of cefotaxime. Activity of all four against methicillin-resistant staphylococci was low. Streptococcus faecalis was inhibited by 16 mg/l of Sch 34343 and 2 mg/l of imipenem. The activity of Sch 34343 was not affected by a beta-lactamase inactivating third generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3897170     DOI: 10.1093/jac/15.suppl_c.155

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Mechanism of action of BAY v 3522, a new cephalosporin with unusually good activity against enterococci.

Authors:  G Amalfitano; A Grossato; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors:  A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].

Authors:  K G Naber; D Adam; A Bauernfeind; E Hönig
Journal:  Infection       Date:  1986       Impact factor: 3.553

4.  Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins.

Authors:  A Bauernfeind
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.